Shield Therapeutics

Shield Therapeutics is a UK-based pharmaceutical company focused on developing innovative treatments for iron deficiency, notably through its flagship product, ACCRUFeR®. Founded in 2008 and headquartered in Newcastle, UK, Shield Therapeutics specializes in specialty pharmaceuticals for iron deficiency. The company has undergone significant growth and development, culminating in an IPO on February 12, 2016, which raised GBP 32. 5 million.

The founder, Christian Schweiger, has a background in pharmaceuticals, and the current leadership includes CEO Greg Madison. Shield Therapeutics has completed two funding rounds, with the total amount raised being GBP 32. 5 million, all achieved by the latest funding round. Shield Therapeutics plc specializes in developing innovative specialty pharmaceuticals aimed at addressing significant unmet medical needs related to iron deficiency.

Their flagship product, ACCRUFeR® (ferric maltol), is a stable, non-salt based oral therapy approved for the treatment of iron deficiency with or without anemia in adults. This product functions by providing a well-tolerated and effective oral iron replacement option, crucial for patients facing challenges with existing therapies. ACCRUFeR® is available in multiple geographical markets including the United States, the European Union, the United Kingdom, and Switzerland. The primary customers include healthcare providers and institutions, while the end users are patients suffering from iron deficiency who seek convenient and effective treatment solutions.

For the year 2024, Shield Therapeutics reported revenue of GBP 32. 18 million and an EBITDA of GBP -21. 44 million. The company generates revenue primarily through the sales of ACCRUFeR®, focusing on direct transactions with healthcare providers and hospitals, leveraging negotiated contracts that may involve bulk purchasing agreements with healthcare institutions.

This pricing structure is designed to accommodate the various markets Shield Therapeutics operates in, ensuring accessibility for healthcare facilities. Following the successful IPO in February 2016, Shield Therapeutics aims to utilize the funding to conduct a Phase III pivotal development program for ST10-021, which involves filing a marketing authorization application. The company is focused on expanding its product offerings and plans to enter new geographic markets, specifically targeting regions that require effective iron deficiency treatments. The strategic use of recent funding will support these initiatives and further establish Shield Therapeutics in the global pharmaceutical landscape.